ACE Technology Guidances communicate recommendations from the MOH Drug Advisory Committee or the MOH Medical Technology Advisory Committee on the funding status and appropriate use of drugs, vaccines or medical technologies that have been evaluated by ACE. The guidances also include the Committee’s rationale for the funding recommendations, and key clinical and economic evidence which informed their deliberations. Plain English Summaries (PES) to explain ACE Technology Guidances are available for patients and the public.

Published on 01 Oct 2020
Last Updated on 19 Dec 2022
A- A+
Abiraterone for treating metastatic prostate cancer Guidance and Plain English Summary (PES) is outdated and has been withdrawn on 19 December 2022.
Please refer to the updated recommendations on Update of MOH List of Subsidised Drugs to include treatments for various cancer conditions here

Abiraterone for treating metastatic prostate cancer (Withdrawn 19 December 2022) PES Abiraterone for treating metastatic prostate cancer (Withdrawn 19 December 2022)